Synthetic cannabidiol - INSYS Therapeutics

Drug Profile

Synthetic cannabidiol - INSYS Therapeutics

Alternative Names: Pharmaceutical cannabidiol (CBD) - INSYS Therapeutics

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator INSYS Therapeutics, Inc
  • Developer California Pacific Medical Center; INSYS Therapeutics, Inc; The University of Montreal Hospital Research Center; University of Chicago
  • Class Analgesics; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Dravet syndrome; Lennox-Gastaut syndrome; Infantile spasms; Glioblastoma; Schizophrenia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Dravet syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dravet syndrome; Lennox-Gastaut syndrome
  • Phase II Drug abuse; Infantile spasms
  • Phase I/II Pain
  • Preclinical Glioblastoma; Peripheral nervous system diseases

Most Recent Events

  • 22 Jul 2016 INSYS Therapeutics plans a phase II trial for Prader-Willi Syndrome (In children, In adolescents, In adults) in USA (PO) (NCT02844933)
  • 01 Jun 2016 Phase-I/II clinical trials in Pain (In volunteers) in USA (PO)
  • 24 May 2016 INSYS Therapeutics completes a phase I/II trial in Epilepsy (In adolescents, In children, In infants) in USA (NCT02324673)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top